ArticleFamilial cancer2009
The prevalence of germ-line TP53 mutations in women diagnosed with breast cancer before age 30.
Article in Familial cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 38 citations in OpenAlex.
- Pedigree analysis exploring the inconsistency between diverse phenotypes and testing criteria for germline TP53 mutations in Chinese women with breast cancer.Breast cancer research and treatment · 2024Article
- Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.International journal of clinical oncology · 2021Article
- Examining the etiology of early-onset breast cancer in the Canadian Partnership for Tomorrow's Health (CanPath).Cancer causes & control : CCC · 2021Article
- TP53 germline mutations in the context of families with hereditary breast and ovarian cancer: a clinical challenge.Archives of gynecology and obstetrics · 2021Article
- Mutation screening of germline TP53 mutations in high-risk Chinese breast cancer patients.BMC cancer · 2020Article
- Li-Fraumeni syndrome heterogeneity.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Genetic counselling of young women with breast cancer for Li-Fraumeni syndrome: a nationwide survey on the experiences and attitudes of genetics professionals.Familial cancer · 2019Article
- TP53 germline mutation testing in early-onset breast cancer: findings from a nationwide cohort.Familial cancer · 2019Article
- Increased access to TP53 analysis through breast cancer multi-gene panels: clinical considerations.Familial cancer · 2018Article
- Next generation sequencing is informing phenotype: a TP53 example.Familial cancer · 2018Article
- Genomic Disparities in Breast Cancer Among Latinas.Cancer control : journal of the Moffitt Cancer Center · 2016Article
- Article
- Prevalence of germline TP53 mutations in HER2+ breast cancer patients.Breast cancer research and treatment · 2013Article
- Article
- No evidence for breast cancer susceptibility associated with variants of BRD7, a component of p53 and BRCA1 pathways.Familial cancer · 2012Article
- Routine TP53 testing for breast cancer under age 30: ready for prime time?Familial cancer · 2012Article
- Breast cancer in young women.Nature reviews. Clinical oncology · 2012Review
- Late onset Li-Fraumeni Syndrome with bilateral breast cancer and other malignancies: case report and review of the literature.BMC cancer · 2012Review
- The tip of the iceberg: a countercurrents series.Current oncology (Toronto, Ont.) · 2012Article
- Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients.Familial cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 12 institutions in 7 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Germ-line mutations in the TP53 gene are rare, but predispose women to a range of cancer types, including early-onset breast cancer. Breast cancers in women from families with the Li-Fraumeni syndrome often occur before age 30. The prevalence of deleterious TP53 mutations in unselected women with early-onset breast cancer is not precisely known. If mutations were found to be sufficiently common, it might be prudent to offer genetic testing to affected women in this age group. We screened the entire TP53 gene in the germ-line DNA from 95 women of various ethnic groups who were diagnosed with breast cancer before age 30, and who had previously been found to be negative for BRCA1 and BRCA2 mutations. No TP53 mutation was found. This study does not support a policy that TP53 testing should be offered routinely to unselected women with early-onset breast cancer in the absence of a family history of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.